US 7364736

US patent 7364736, titled "Antibodies to OPGL," was assigned to Amgen Inc.. The inventors are William J. Boyle, Francis H. Martin, Jose R. Corvalan, and C. Geoffrey Davis. The patent was filed on June 25, 2002, and issued on April 29, 2008.

The abstract describes the invention as relating to antibodies that bind osteoprotegerin ligand (OPGL). It also covers polynucleotides and amino acid sequences for these antibodies (particularly variable regions and complementarity determining regions (CDRs) of the light and heavy chain immunoglobulin molecules). The patent further provides hybridoma cell lines producing these immunoglobulins and monoclonal antibodies, purified human monoclonal antibodies against human OPGL, and methods for their production and use in treating osteopenic disorders and other conditions.

A plain-language overview of the independent claims is as follows:

• Claim 1: This claim covers an isolated antibody having a heavy chain with the amino acid sequence of SEQ ID NO: 2 and a light chain with the amino acid sequence of SEQ ID NO: 4.
• Claim 10: This claim covers an isolated antibody where the heavy chain's variable region contains the amino acid sequence of SEQ ID NO: 13, and the light chain's variable region contains the amino acid sequence of SEQ ID NO: 14.
• Claim 19: This claim covers an isolated antibody where the heavy chain's variable region is at least 90% identical to SEQ ID NO: 13, and the light chain's variable region is at least 90% identical to SEQ ID NO: 14. This antibody must also interact with osteoprotegerin ligand (OPGL).
• Claim 22: This claim covers an isolated heavy chain, or a fragment thereof, comprising the amino acid sequence of SEQ ID NO: 2.
• Claim 25: This claim covers an isolated heavy chain that includes a variable region and a constant region, where the variable region (or a fragment of it) has the amino acid sequence of SEQ ID NO: 13.
• Claim 28: This claim covers an isolated light chain, or a fragment thereof, comprising the amino acid sequence of SEQ ID NO: 4.
• Claim 31: This claim covers an isolated light chain, or a fragment thereof, comprising the amino acid sequence of SEQ ID NO: 14.
• Claim 34: This claim covers a single-chain antibody that includes a heavy chain (or fragment) having the amino acid sequence of SEQ ID NO: 2 and a light chain (or fragment) having the amino acid sequence of SEQ ID NO: 4.
• Claim 36: This claim covers a single-chain antibody where the heavy chain variable region (or fragment) has the amino acid sequence of SEQ ID NO: 13, and the light chain variable region (or fragment) has the amino acid sequence of SEQ ID NO: 14.
• Claim 38: This claim covers a pharmaceutical composition containing a therapeutically effective amount of the antibody from Claim 1, combined with standard pharmaceutical diluents, carriers, or other excipients.
• Claim 43: This claim describes a method for treating an osteopenic disorder in a patient by administering a therapeutically effective amount of the antibody from Claim 1 to that patient.
• Claim 48: This claim describes a method for treating an osteopenic disorder in a patient by administering the pharmaceutical composition described in Claim 38.
• Claim 53: This claim describes a method for treating an inflammatory condition associated with bone loss in a patient, by administering the pharmaceutical composition of Claim 38.
• Claim 54: This claim describes a method for treating an autoimmune condition associated with bone loss in a patient, by administering the pharmaceutical composition of Claim 38.
• Claim 55: This claim describes a method for detecting the level of OPGL in a biological sample by contacting the sample with the antibody from Claim 1.
• Claim 57: This claim covers a pharmaceutical composition comprising a therapeutically effective amount of an antibody that interacts with OPGL, along with a therapeutically effective amount of at least one additional therapeutic agent.
• Claim 61: This claim describes a method for treating a bone disorder in a patient by administering a therapeutically effective amount of an antibody that interacts with OPGL, and also administering a therapeutically effective amount of at least one additional therapeutic agent.
• Claim 65: This claim describes a method for treating an inflammatory condition with attendant bone loss in a patient by administering a therapeutically effective amount of an antibody that interacts with OPGL and at least one additional therapeutic agent.
• Claim 66: This claim describes a method for treating an autoimmune condition with attendant bone loss in a patient by administering a therapeutically effective amount of an antibody that interacts with OPGL and at least one additional therapeutic agent.
• Claim 67: This claim describes a method for treating rheumatoid arthritis in a patient by administering a therapeutically effective amount of an antibody that interacts with OPGL and at least one additional therapeutic agent.
• Claim 68: This claim describes a method for treating an osteopenic disorder in a patient by administering a therapeutically effective amount of an antibody that interacts with OPGL, specifically an antibody with a dissociation constant (Kd) between approximately 0.23 and 0.29 nM.
• Claim 69: This claim describes a method for treating an osteopenic disorder in a patient by administering a therapeutically effective amount of an antibody that interacts with OPGL, specifically an antibody with a dissociation constant (Kd) of less than 0.23 nM.

A search for US patent 7364736 in the USPTO database confirms the details provided by Google Patents. The patent is listed as "Expired - Lifetime, expires 2025-02-19".

Regarding CAFC 2026 dockets, no specific cases involving US patent 7364736 filed in 2026 were found in the search results. However, the Google Patents page indicates that the patent family has ongoing litigation, with several US cases filed in New Jersey and Massachusetts District Courts in 2023, 2024, and 2025. These are district court cases, not filings with the Court of Appeals for the Federal Circuit.